Kristie L. Kahl

Results of a phase I trial presented showed that the agent BLU-285 (Avapritinib) agent was well tolerated among patients with an advanced or aggressive form of systemic mastocytosis (ASM), a rare blood disorder that originates in mast cells.

Shortening the intervals between chemotherapy cycles or administering the drugs sequentially compared to current techniques reduces early-stage breast cancer recurrence and mortality, study shows.